The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study
| Autor: | Maria T. Abreu, Maria A. Quintero, Anjali Jain, Richard Kirkland, Fred Princen, Jamie S. Barkin, Andres Yarur, Amar R. Deshpande, Sharat Singh, Daniel A. Sussman |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Pathology
medicine.medical_specialty Crohn's disease Necrosis business.industry Gastroenterology medicine.disease Ulcerative colitis Inflammatory bowel disease Infliximab Serology 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis medicine Adalimumab 030211 gastroenterology & hepatology Tumor necrosis factor alpha medicine.symptom business medicine.drug |
| Zdroj: | Gut. 65:249-255 |
| ISSN: | 1468-3288 0017-5749 |
| Popis: | Objective The aim of this study was to assess the correlation between serum and intestinal anti-tumour necrosis factor (TNF) levels, and their relationship to endoscopic disease activity and levels of TNF. Design Cross-sectional study of 30 patients receiving treatment with infliximab or adalimumab for Crohn9s disease or UC. For each patient, a sample of serum was matched to tissue biopsies. Endoscopic and histological disease activity was recorded for each tissue sample. Results There was a significant positive correlation between anti-TNF in serum and tissue (r=0.3920, p=0.002), especially in uninflamed tissue (r=0.50, p Conclusions Our data suggest that local tissue inflammation characterised by high levels of TNF serves as a sink for anti-TNF. We further postulate that some patients with high serum anti-TNF levels have active disease because tissue levels of anti-TNF are insufficient to neutralise local TNF production. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|